A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 24, Issue 4, 2014, Pages 170-179

  Emslie, Graham J ^a,b   Prakash, Apurva ^b   Zhang, Qi ^b   Pangallo, Beth A ^b   Bangs, Mark E ^b   March, John S ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; FLUOXETINE; PLACEBO; ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR; THIOPHENE DERIVATIVE;

ADOLESCENT; ADOLESCENT DISEASE; AGGRESSION; ARTICLE; AUTOMUTILATION; BODY MASS; CHILD; CHILD PSYCHIATRY; CHILDHOOD DISEASE; CHILDREN DEPRESSION RATING SCALE REVISED; CLINICAL GLOBAL IMPRESSION SCALE; COLUMBIA SUICIDE SEVERITY RATING SCALE; CONTROLLED STUDY; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV-TR; ELEVATED BLOOD PRESSURE; FATIGUE; FEMALE; HALLUCINATION; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RISK ASSESSMENT; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE ATTEMPT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UPPER ABDOMINAL PAIN; VOMITING; CLINICAL TRIAL; COMPARATIVE STUDY; DEPRESSIVE DISORDER, MAJOR; DOSE RESPONSE; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PSYCHOLOGICAL RATING SCALE; SEVERITY OF ILLNESS INDEX; SUICIDE; TREATMENT OUTCOME;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; CHILD; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; SUICIDAL IDEATION; SUICIDE; THIOPHENES; TREATMENT OUTCOME;

EID: 84901264035     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2013.0096     Document Type: Article

References (23)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision. Washington, DC: American Psychiatric Association; 2000
2. Atkinson SD, Prakash A, Zhang Q, Pangallo BA, Bangs ME, Emslie GJ, March JS: A double-blind, efficacy and safety study of duloxetine flexible doses in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 24:180-189, 2014
3. Bridge JA, Birmaher B, Iyengar S, Barbe RP, Brent DA: Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry 166:42-49, 2009
4. Cymbalta Full Prescribing Information. Available at http://pi.lilly .com/us/Cymbalta-pi.pdf. Accessed March 1, 2014
5. Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, Nilsson M, Jacobson JG: Fluoxetine for acute treatment of depression in children and adolescents: A placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 41:1205-1215, 2002
6. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, Rintelmann J: A double-blind, randomized, placebocontrolled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 54:1031-1037, 1997
7. Emslie GJ, Ventura D, Korotzer A, Tourkodimitris S: Escitalopram in the treatment of adolescent depression: A randomized placebocontrolled multisite trial. J Am Acad Child Adolesc Psychiatry 48:721-729, 2009
8. Guy W: ECDEU assessment manual for psychopharmacology. Rockville, MD: National Institute of Mental Health, Psychopharmacology Research Branch; 1976
9. Hammad TA, Laughren T, Racoosin J: Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63:332-339, 2006
10. Kenward MG, Roger JH: Small sample inference for fixed effects from restricted maximum likelihood. Biometrics 53:983-997, 1997
11. Lieberman JA, Greenhouse J, Hamer RM, Krishnan KR, Nemeroff CB, Sheehan DV, Thase ME, Keller MB: Comparing the effects of antidepressants: Consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology 30:445-60, 2005
12. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J: Fluoxetine, cognitivebehavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 292:807-820, 2004
13. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents: Update on the 1996 task force report on high blood pressure in children and adolescents: A working group report from the National High Blood Pressure Education Program. Pediatrics 114:555-576, 2004
14. National Research Council: The Prevention and Treatment of Missing Data in Clinical Trials. Panel on Handling Missing Data in Clinical Trials. Committee on National Statistics, Division of Behavioral and Social Sciences and Education. Washington, DC: The National Academies Press; 2010
15. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ: The Columbia-Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 168:1266-1277, 2011
16. Posner K, Oquendo MA, Gould M, Stanley B, Davies M: Columbia Classification Algorithm of Suicide Assessment (C-CASA): Classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 164:1035-1043, 2007
17. Poznanski EO, Cook SC, Carroll BJ: A depression rating scale for children. Pediatrics 164:442-450, 1979
18. Poznanski EO, Grossman JA, Buchsbaum Y, Banegas M, Freeman L, Gibbons R: Preliminary studies of the reliability and validity of the Children's Depression Rating Scale. J Am Acad Child Psychiatry 23:191-197, 1984
19. Prakash A, Lobo E, Kratochvil CJ, Tamura RN, Pangallo BA, Bullok KE, Quinlan T, Emslie GJ, March JS: An open-label safety and pharmacokinetics study of duloxetine in pediatric patients with major depression. J Child Adolesc Psychopharmacol 22:48-55, 2012
20. Pritchett YL, Marciniak MD, Corey-Lisle PK, Berzon RA, Desaiah D, Detke MJ: Use of effect size to determine optimal dose of duloxetine in major depressive disorder. J Psychiatr Res 41:311-318, 2007
21. Rutherford BR, Roose SP: A model of placebo response in antidepressant clinical trials. Am J Psychiatry 170:723-733, 2013
22. Sheehan DV, Sheehan KH, Shytle RD, Janavs J, Bannon Y, Rogers JE, Milo KM, Stock SL, Wilkinson B: Reliability and validity of the Mini International Neuropsychiatric interview for Children and Adolescents (MINI-KID). J Clin Psychiatry 71:313-326, 2010
23. Wagner KD, Jonas J, Findling RL, Ventura D, Saikali K: A doubleblind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry 45:280-288, 2006